National Epilepsy Day

Historical article. Study and recruitment information reflects its publication date, not the current status.

Today, May 24, the National Epilepsy Day, created in 2006 is celebrated in order to raise awareness and inform the entire population about this disease and about the reality and needs of patients with epilepsy.

Today, May 24, the National Epilepsy Day, created in 2006 is celebrated in order to raise awareness and inform the entire population about this disease and about the reality and needs of patients with epilepsy. According to the World Health Organization (WHO) in the world there are 50 million people with epilepsy, there is a significant group where the crises are unnoticed by the patient or family. Our Chief of Service, Director of Neurosciences Unit and General Coordinator of Neuroreca , Dr. Pedro Serrano, is a specialist and with an excellent experience in epilepsy has offered an interview in the newspaper La Opinion de Málaga, which you can read here online or on page 12 of the printed edition. As part of this news and quoted textually: Epilepsy is a disease characterized by abnormal electrical activity in the brain that causes unusual seizures, behaviors and sensations, and even loss of consciousness. “It is a heterogeneous disease, as it is a set of diseases,” he explains. Serrano News Interview Our Clinical Trials Unit has in recruitment the following epilepsy tests: Realize (CVL-865-SZ-001 / 002): Randomized, double-blind, placebo-controlled, multicentered study and parallel groups about CVL-865 as complementary treatment in adults with drug-resistant focal start-up seizures Legione (AIE001): Phase 2, randomized, double-blind, placebo-controlled and multicentered study to assess the effectiveness, safety and pharmacokinetics of rozanolixizumab in adults with autoimmune encephalitis associated with antibodies directed against protein 1 inactive of leucine-rich glioma The following essay will soon be active: EPY2001 (40411813EPY2001): Randomized, double-blind, controlled study placebo of parallel and multicenter groups to assess the effectiveness, security and tolerability of JNJ-40411813 as complementary treatment in subjects with epileptic crisis of focal start with sub-optimal response to miltiracetam If you want to report or participate in some of our trials, you can contact us here.

View all news